The albumin-to-creatinine ratio is the number on your lab report that tells you how much albumin — the most abundant protein in blood — your kidneys are leaking into your urine, adjusted so the result is comparable regardless of how concentrated or dilute your urine was when the sample was collected. It is abbreviated ACR or UACR (urine albumin-to-creatinine ratio) depending on the lab, but both refer to the same measurement.
If you have diabetes, high blood pressure, or a family history of kidney disease, your ACR is one of the two most important kidney numbers you should know — the other being your eGFR. Together, these two values define your CKD stage and your risk of kidney disease progression according to international guidelines. This guide explains what the albumin-to-creatinine ratio is, how to read and track your result, what changes mean for your treatment, and when an abnormal ACR requires action.
What Is the Albumin-to-Creatinine Ratio?
The albumin-to-creatinine ratio is calculated from a spot urine sample: the laboratory measures the concentration of albumin in the urine (in milligrams per deciliter) and the concentration of creatinine (in grams per deciliter), then divides one by the other to produce a result expressed as milligrams of albumin per gram of creatinine — written mg/g.
The reason creatinine is used as the denominator is straightforward. Urine concentration varies enormously depending on how much fluid you have drunk, the weather, your activity level, and many other factors. A person who has drunk very little will produce concentrated urine; the same person after drinking a liter of water will produce dilute urine. If you measured albumin concentration alone, the result would reflect both how much albumin your kidneys are leaking and how concentrated your urine happens to be that day. Dividing by urine creatinine — which reflects muscle mass and is relatively stable in the same person from day to day — corrects for this variability. The ratio is interpretable regardless of hydration state, which is why it replaced timed urine collections for routine clinical monitoring.
The ACR has been validated across decades of research in diabetic nephropathy, hypertensive kidney disease, and general CKD populations as a reliable, reproducible surrogate for 24-hour albumin excretion rate — without the logistical burden of a 24-hour urine collection.
ACR Normal Range and KDIGO Categories
The KDIGO 2012 CKD guidelines established three albuminuria categories based on ACR that are now universally used in nephrology and endocrinology:
A1 — ACR less than 30 mg/g: Normal to mildly increased. In people with no risk factors for kidney disease, an A1 result requires no specific intervention. In people with diabetes or hypertension, annual monitoring is recommended because albumin can rise gradually into the A2 range over time, and catching that transition early is the whole point.
A2 — ACR 30 to 300 mg/g: Moderately increased. This is the range previously called “microalbuminuria” — a term that has fallen out of favor because the prefix suggests the finding is trivially small. It is not. An ACR in the A2 range in a diabetic patient represents the earliest detectable sign of diabetic kidney disease. It appears years before creatinine rises or eGFR falls. This is the window in which treatment is most effective at reversing or halting kidney damage. In non-diabetic patients, A2 albuminuria is an independent risk factor for CKD progression and cardiovascular events.
A3 — ACR greater than 300 mg/g: Severely increased. This range was previously called “macroalbuminuria” or “overt proteinuria.” At this level, glomerular damage is significant, and the risk of progressive CKD and cardiovascular events is substantially elevated. If the ACR exceeds approximately 3,500 mg/g — or if 24-hour protein excretion exceeds 3.5 grams per day — the patient is in the nephrotic range. Nephrotic-range proteinuria is a distinct clinical entity characterized by edema, low serum albumin, elevated cholesterol, and markedly elevated thrombosis risk, and it requires urgent evaluation.
One nuance worth understanding: some laboratories report sex-specific normal ranges. Men tend to have higher muscle mass and therefore higher urine creatinine than women, which means that for the same albumin excretion rate, women’s ACR will be slightly higher. The KDIGO guidelines use a single threshold of 30 mg/g for both sexes, but some clinical contexts use sex-specific cutoffs of approximately 17 mg/g for men and 25 mg/g for women as the upper limit of normal. This does not change the A1/A2/A3 framework — it simply refines where normal ends within the A1 range.
How to Calculate ACR — and Why It Varies Between Tests
Your laboratory reports the ACR directly — you do not need to calculate it yourself. However, understanding the formula helps explain why ACR results can vary between tests even in the same person, and why this variation is not always a cause for alarm.
The formula is: ACR (mg/g) = urine albumin concentration (mg/dL) × 10 ÷ urine creatinine concentration (mg/dL). The factor of 10 converts the albumin from mg/dL to mg/g by adjusting for the difference in units. What this means practically is that the denominator — urine creatinine — has an important effect on the result. If your urine creatinine is low (because your sample was dilute, or because you have low muscle mass), the denominator is small and the ACR is higher even if albumin excretion has not changed. If your urine creatinine is high (concentrated urine or high muscle mass), the denominator is large and the ACR appears lower.
This is why people with very low muscle mass — elderly patients, patients with sarcopenia, or people who are chronically malnourished — may have ACR results that are slightly higher than their true albumin excretion rate would suggest. In these populations, a borderline ACR result may warrant confirmation with a timed urine collection to assess true albumin excretion. Similarly, people with very high muscle mass from athletic training may have a slightly lower ACR than their actual albumin excretion rate, because the large creatinine denominator suppresses the ratio.
Tracking ACR Over Time — What the Trend Means
A single ACR value provides a snapshot. The trend over time provides the story. When managing kidney disease or preventing it in high-risk populations, the direction and speed of change in ACR over months and years is often more informative than any individual result.
A rising ACR over one to two years — even if each individual value falls within a range that might seem borderline in isolation — is a significant clinical signal. It indicates that glomerular damage is accumulating: the kidney barrier is becoming progressively leakier. Importantly, ACR can rise for months to years before eGFR begins to fall. This means that a patient whose eGFR is stable but whose ACR is trending upward is not in a safe holding pattern — they are on a trajectory toward eGFR decline. The ACR change is the early warning system.
Conversely, a declining ACR on treatment is one of the most encouraging signs in CKD management. It indicates that the treatment is reducing glomerular stress and leakage, and clinical trials have established that sustained ACR reduction corresponds to slower loss of kidney function over years.
To calculate the percentage change in ACR between two visits: subtract the earlier value from the later value, divide by the earlier value, and multiply by 100. If your ACR was 200 mg/g six months ago and is now 120 mg/g, the calculation is (120 − 200) ÷ 200 × 100 = −40%. That is a 40 percent reduction — a clinically meaningful improvement that indicates your treatment is working. If your ACR was 200 and is now 320, the calculation is (320 − 200) ÷ 200 × 100 = +60%. That is a 60 percent increase, which warrants prompt attention regardless of where your eGFR sits.
A stable ACR in the low A2 range (for example, 35 to 45 mg/g across multiple measurements over two years) with a stable eGFR and well-controlled blood pressure and blood sugar is a lower-risk situation — not zero risk, but one where the primary goal is continued monitoring and maintenance of the current level of control.
ACR and Treatment Response — The 30% Rule
Clinical trials of kidney-protective therapies use ACR reduction as a surrogate endpoint — a measurable proxy for the long-term outcome of interest (preserving kidney function). The threshold most commonly cited is a 30% or greater reduction in ACR from baseline. This is the minimum reduction considered clinically meaningful across multiple major trials.
In the CREDENCE trial, canagliflozin (an SGLT-2 inhibitor) reduced ACR by approximately 31% in diabetic kidney disease patients, and this reduction was accompanied by a 34% reduction in the composite kidney endpoint over 2.6 years. In the DAPA-CKD trial, dapagliflozin reduced ACR by roughly 30%, with similar kidney-protective effects in both diabetic and non-diabetic CKD. These results established the ACR reduction as a biologically meaningful, not just statistically convenient, endpoint.
ACE inhibitors and ARBs typically reduce ACR by 30 to 50 percent in patients with diabetic nephropathy, depending on the baseline ACR, the blood pressure response, and the specific drug and dose used. Finerenone, tested in the FIDELIO-DKD and FIGARO-DKD trials in patients with diabetic kidney disease on background RAAS blockade, reduced ACR by approximately 31% compared to placebo — and is additive to, not a replacement for, ACE inhibitors or ARBs.
After starting or changing a proteinuria-reducing treatment, recheck ACR in three to six months to assess response. If the ACR has not decreased by at least 30 percent despite what appears to be an adequate treatment trial, the possibility of incomplete RAAS blockade, inadequate blood pressure control, dietary sodium excess (which blunts RAAS blocker efficacy), or a treatment-resistant cause of proteinuria should be explored. Referral to nephrology is appropriate if ACR continues to rise or fails to respond to standard treatment.
ACR vs. PCR — Which One Does Your Lab Report?
The albumin-to-creatinine ratio (ACR) measures only albumin in the urine. The protein-to-creatinine ratio (PCR), also called the urine protein-creatinine ratio or UPCR, measures total protein — albumin plus all other proteins that may be present in the urine. The distinction matters for interpretation.
In the most common kidney diseases — diabetic nephropathy, hypertensive nephrosclerosis, and most forms of glomerulonephritis — albumin constitutes 70 to 80 percent or more of the total urine protein. In these conditions, ACR and PCR results are strongly correlated, and either can be used for monitoring. The rough conversion is ACR ≈ 0.7 to 0.8 × PCR, though this relationship varies between individuals and disease states.
However, in conditions where non-albumin proteins dominate the urine — such as multiple myeloma (immunoglobulin light chains) or certain forms of tubular proteinuria — ACR may significantly underestimate the true proteinuria burden. Patients with suspected plasma cell dyscrasias require urine protein electrophoresis (UPEP) rather than relying on ACR alone.
The practical implication: be consistent within a monitoring program. If your nephrologist has been following your ACR, continue monitoring ACR. If your care team uses PCR, continue with PCR. Switching between ACR and PCR mid-course makes trend interpretation difficult because the two ratios are not numerically equivalent.
The KDIGO Heat Map — ACR and eGFR Together
The most important advance in CKD risk stratification introduced by the KDIGO 2012 guidelines was the recognition that kidney prognosis cannot be defined by eGFR or ACR alone — both are required together. The KDIGO heat map places eGFR categories (G1–G5) on one axis and albuminuria categories (A1–A3) on the other, color-coded from green (low risk) through yellow, orange, and red (very high risk).
Two patients with the same eGFR of 50 mL/min/1.73m² (both in stage G3a) occupy very different risk categories depending on their ACR. A patient with ACR 10 mg/g (A1) is at moderate risk of CKD progression and cardiovascular events. A patient with ACR 150 mg/g (A2) is at high risk. A patient with ACR 400 mg/g (A3) is at very high risk — even though all three share the same eGFR. This is because ACR independently predicts the speed of eGFR decline: higher ACR at any given eGFR predicts faster progression toward kidney failure.
Conversely, two patients with the same ACR of 50 mg/g (both A2) have different prognoses depending on their eGFR. The patient with eGFR 75 (G2) is at moderate risk; the patient with eGFR 35 (G3b) is at high risk. The combination of declining eGFR and rising ACR — the trajectory that represents active kidney damage from two measurable directions — produces the highest risk classification and the most urgent indication for treatment intensification. For the eGFR side of this picture, see the guide on what is eGFR.
Who Needs ACR Testing and How Often
The frequency of ACR testing depends on your current results, your underlying conditions, and whether you are being treated for kidney disease or monitoring for its early development.
Diabetes (type 1 or type 2): The American Diabetes Association recommends annual ACR testing starting at the time of type 2 diabetes diagnosis, and starting after 5 years of disease duration for type 1 diabetes. If your ACR is already in the A2 range, more frequent testing — every 6 months — allows earlier detection of progression and earlier assessment of treatment response.
Hypertension with CKD risk factors: Annual ACR testing in patients with hypertension and additional risk factors (obesity, age over 60, family history of kidney disease, prior AKI) can detect early hypertensive nephrosclerosis before eGFR changes.
Known CKD: Patients with stable CKD at moderate risk are monitored every 6 to 12 months; those at high or very high risk (G3b–G5 or A2–A3) are monitored every 3 to 6 months. More frequent monitoring is appropriate when treatment is being initiated or adjusted.
Post-acute kidney injury: A baseline ACR and follow-up test at 3 months after AKI recovery is recommended, as AKI is a risk factor for developing CKD and persistent albuminuria post-AKI is an early marker of this transition.
What Makes ACR Results Unreliable
Because ACR is a ratio derived from a spot urine sample, it is subject to several sources of variability that can produce misleading results if not accounted for:
- Exercise: Strenuous physical activity within 24 to 48 hours of the test can transiently elevate albumin excretion. Collect the urine sample on a rest day.
- Urinary tract infection: Inflammation releases proteins into the urine. Repeat the ACR after the infection has been treated and cleared.
- Fever and acute illness: Systemic inflammation transiently increases glomerular permeability. Repeat after full recovery.
- Menstrual contamination: Use a midstream catch collected away from the menstrual period, or delay testing until after menstruation is complete.
- Pregnancy: Glomerular hyperfiltration during normal pregnancy makes the ACR unreliable. The 24-hour urine protein collection is preferred for assessing proteinuria in pregnancy.
- Extreme hydration states: Consistent first-morning collection conditions minimize variability from concentration differences.
The fundamental safeguard is the KDIGO requirement that at least two of three tests be elevated, over approximately three months, before persistent albuminuria is diagnosed. A single elevated ACR result should always prompt a repeat under controlled conditions before triggering treatment changes.
Conclusion
The albumin-to-creatinine ratio is not just a lab value — it is a dynamic indicator of kidney barrier integrity that can be tracked over time, used to assess treatment response, and combined with eGFR to produce the most complete available picture of kidney health and prognosis. Understanding what your ACR result means, what category it places you in, and how it is changing over time transforms a single laboratory number into an actionable part of your kidney care.
If your ACR is in the A2 or A3 range, work with your provider to identify the underlying cause, initiate the appropriate treatment, and establish a follow-up schedule to track your response. A 30 percent or greater reduction in ACR is the target — and achieving it with an ACE inhibitor, ARB, SGLT-2 inhibitor, or their combination is achievable for most patients. For the full picture of kidney laboratory testing, see the companion articles on urine albumin test explained, creatinine blood test explained, BUN blood test, and what is chronic kidney disease.
ACR in Special Populations
While the KDIGO A1/A2/A3 framework applies across most adults, certain populations require additional context when interpreting ACR results.
Older adults. With aging, the number of functioning nephrons declines gradually through a process called glomerulosclerosis — the fibrotic replacement of glomeruli that occurs even in the absence of diabetes, hypertension, or specific kidney disease. This age-related loss of filtering units can cause a modest elevation in ACR, typically into the low A2 range, that reflects aging rather than a progressive pathological process. In an older adult with a stable ACR of 35 to 50 mg/g, a stable eGFR for their age, well-controlled blood pressure, and no diabetes, the clinical significance of the ACR elevation may be lower than the same value in a 45-year-old. However, a rising ACR in an older adult — even from a low A2 baseline — still warrants investigation, because the distinction between age-related change and superimposed disease is not always visible in the number alone.
People with low muscle mass. As discussed in the section on how to calculate ACR, low urine creatinine from sarcopenia, malnutrition, or advanced age can inflate the ACR denominator effect. A 78-year-old woman with significant muscle loss may have a urine creatinine of 40 mg/dL where a 40-year-old woman might have 80 mg/dL — and at the same absolute albumin excretion, the older patient’s ACR will be twice as high. When an ACR result seems inconsistent with other markers of kidney health, a timed 24-hour urine albumin collection provides a muscle-mass-independent reference value.
People with type 1 diabetes. The trajectory of diabetic nephropathy in type 1 diabetes is well-characterized: sustained hyperglycemia leads to glomerular hyperfiltration in the first years, followed by the appearance of microalbuminuria (A2) typically after 5 or more years of disease. The ADA recommends beginning annual ACR screening after 5 years of type 1 diabetes duration, specifically because the first 5 years carry a low probability of nephropathy. Once A2 albuminuria is identified, the disease progression trajectory in type 1 is similar to type 2 if left untreated — but can be substantially slowed with tight glycemic control, RAAS blockade, and SGLT-2 inhibitors where appropriate.
People with autoimmune kidney disease. Conditions such as lupus nephritis, IgA nephropathy, ANCA vasculitis, and membranous nephropathy cause significant albuminuria — often in the A3 range — through immune-mediated glomerular injury that is pathologically distinct from diabetic or hypertensive nephrosclerosis. In these patients, the ACR is used not just for diagnosis but for monitoring disease activity and treatment response. A falling ACR during immunosuppressive therapy indicates remission; a rising ACR signals relapse. The interpretation of ACR trends in autoimmune nephritis requires specialist involvement, as the relationship between ACR changes and underlying histological activity is more complex than in metabolic kidney disease.
Practical Steps After an Abnormal ACR
If your ACR comes back elevated — in the A2 or A3 range — on a first test, the appropriate response is not immediate treatment but confirmation and context. Here is the sequence most guidelines recommend:
Step 1: Repeat the test in 2 to 4 weeks under controlled conditions — first morning void, no vigorous exercise in the prior 48 hours, no acute illness or fever. If the first elevation occurred during a UTI or febrile illness, wait until the acute condition has fully resolved before repeating.
Step 2: If the second test is also elevated, order a third test within 3 months. Two of three elevated results — all collected under standard conditions — confirm persistent albuminuria and establish the KDIGO category.
Step 3: Identify the cause. For most adults with confirmed A2 albuminuria, the most likely causes are diabetic nephropathy (if diabetes is present) or hypertensive nephrosclerosis (if hypertension is present). A complete kidney evaluation includes a creatinine blood test and eGFR calculation, a BUN test, a urinalysis with microscopy (to look for red cell casts or other signs of glomerulonephritis), and a blood pressure measurement. In younger patients, patients without clear risk factors, or patients with A3 albuminuria, nephrology referral is appropriate to exclude rarer causes.
Step 4: Begin treatment appropriate to the identified cause — RAAS blockade if not already in place, SGLT-2 inhibitor where indicated, blood pressure and blood sugar optimization — and schedule a repeat ACR in 3 to 6 months to assess response. The goal of a 30% or greater reduction in ACR from baseline applies from the first treatment evaluation onward.
Step 5: Establish ongoing monitoring at a frequency appropriate to your risk category and treatment response. An ACR that is falling on treatment with stable eGFR is the best-case scenario; an ACR that is rising despite treatment, or that is associated with a declining eGFR, warrants nephrology involvement and consideration of additional workup including kidney biopsy if the cause remains unclear.
Sources: National Kidney Foundation — Protein in Urine | NIDDK — CKD Tests & Diagnosis | Mayo Clinic — Microalbumin Test
I shared this article on albumin-to-creatinine ratio: what adults should know with my doctor and they appreciated the level of detail. The specific numbers and thresholds mentioned are exactly what I needed to understand my results. Exactly the kind of evidence-based information that is hard to find in one place.
Finally a resource that explains albumin-to-creatinine ratio: what adults should know in plain language. I especially valued the explanation of why these recommendations exist, not just what they are. Keep up this kind of thorough health journalism — it genuinely helps patients like me.
As someone dealing with this personally, the albumin-to-creatinine ratio: what adults should know section was very helpful. I appreciate that the article is careful about distinguishing between what is known and what is still being researched. Appreciate the effort that went into researching and writing this — it shows.